Zobrazeno 1 - 7
of 7
pro vyhledávání: '"R Gracia Piquer"'
Autor:
R Fresquet Molina, JM Vinuesa Hernando, M Zurera Berjaga, Mercedes Gimeno, I Varela Martínez, MA Alcácera López, P Gómez Rivas, R Gracia Piquer
Publikováno v:
Section 5: Patient safety and quality assurance.
Background and importance The inhibitor of cyclin dependent kinases 4 and 6, palbociclib, was a major advance in the treatment of metastatic breast cancer. Aim and objectives To describe the effectiveness and incidence of neutropenia with palbociclib
Autor:
V Acín Garcés, C Seral García, JM Vinuesa Hernando, R Gracia Piquer, E Morte Romea, R Fresquet Molina, M. Arenere Mendoza, Mercedes Gimeno
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Clostridium difficile disease (CDD) is the leading cause of infectious diarrhoea in the hospital environment. Aim and objectives The objective was to evaluate the characteristics of patients with CDD prior to the implementat
Autor:
R Fresquet Molina, V Acín Garcés, M. Arenere Mendoza, Mercedes Gimeno, C Seral García, JM Vinuesa Hernando, E Morte Romea, R Gracia Piquer
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Clostridium difficile disease (CDD) is the main cause of nosocomial diarrhoea. Aim and objectives To evaluate the adequacy of treatment of CDD prior to implementation of the checklist for the diagnosis and treatment of CDD.
Autor:
JM Vinuesa Hernando, M. J. Crusells Canales, I. Sanjoaquin Conde, M Gimeno Gracia, MA Alcácera López, A Frutos Perez-Surio, R Gracia Piquer, S Malo Fumanal, S. Letona Carbajo
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance The effectiveness of current antiretroviral treatments has prolonged the survival of HIV patients, and with age, the prevalence of comorbidities increases. The new clinical conditions of these patients may cause potentially
Autor:
MJ Nebot Villacampa, MA Alcácera López, JM Vinuesa Hernando, I Varela Martínez, R Gracia Piquer, T Salvador Gómez, M. Arenere Mendoza, R Fresquet Molina, FJ Campos Montellano, M Galindo Allueva
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Since the first biosimilar drug was authorised, medicine agencies have promoted their use. However, interchangeability or switching are different in each country, creating disparity in their use. Aim and objectives To measur
Autor:
T Salvador Gómez, R Fresquet Molina, O Horna Oreja, MA Alcácera López, M Gimeno Gracia, JM Vinuesa Hernando, A Frutos Perez-Surio, R Gracia Piquer, FJ Campos Montellano, M Galindo Allueva
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Adalimumab and etanercept are two of the most used biologic drugs worldwide in a variety of chronic diseases. The introduction of biosimilar drugs (BS) for both has revolutionised the market and may enable more patients to a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.